ES2000615A6 - Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" - Google Patents

Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"

Info

Publication number
ES2000615A6
ES2000615A6 ES8601533A ES8601533A ES2000615A6 ES 2000615 A6 ES2000615 A6 ES 2000615A6 ES 8601533 A ES8601533 A ES 8601533A ES 8601533 A ES8601533 A ES 8601533A ES 2000615 A6 ES2000615 A6 ES 2000615A6
Authority
ES
Spain
Prior art keywords
mak
reducing conditions
procedure
preparation
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8601533A
Other languages
English (en)
Inventor
Klaus Bosslet
Gerhard Luben
Ernst-Jurgen Kanzy
Hans-Harald Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES2000615A6 publication Critical patent/ES2000615A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN EL ANTICUERPO MONOCLONAL DESIGNADO COMO MAK 436/15 DEL ISOTIPO-IGG3 CON CADENA KAPPA, QUE REACCIONA CON UNA GLICOPROTEINA (ANTIGENO 1), QUE TIENE UN PESO MOLECULAR (PM) SUPERIOR A 200 KDA EN CONDICIONES NO REDUCTORAS, EL ANTICUERPO MONOCLONAL DESIGNADO COMO MAK 494/32 DEL ISOTIPO -IGG1 CON CADENA KAPPA QUE REACCIONA CON UNA GLICOPROTEINA (ANTIGENO 2), QUE TIENE UN PM SUPERIOR A 200 KDA TANTO EN CONDICIONES NO REDUCTORAS COMO EN CONDICIONES REDUCTORAS, Y DOS ANTICUERPOS MONOCLONALES DESIGNADOS COMO MAK 495/19 Y 495/36 DEL ISOTIPO-IGG3 CON CADENA KAPPA, QUE REACCIONAN CON UNA GLICOPROTEINA (ANTIGENO 3), QUE TIENE UN PM SUPERIOR A 200 KDA TANTO EN CONDICIONES NO REDUCTORAS COMO EN CONDICIONES REDUCTORAS, ASI COMO UN PROCEDIMIENTO PARA SU PREPARACION. ESTOS ANTICUERPOS SE PUEDE UTILIZAR PARA LA FIJACION A LOS CORRESPONDIENTES ANTIGENOS SOBRE CELULAS Y TEJIDOS PORTADORES DE ESTOS ANTIGENOS Y, POR LO TANTO, SE PUEDEN UTILIZAR COMO AGENTES PARA DIAGNOSTICO, AGENTES TERAPEUTICOS O COMOVEHICULOS PARA UNA SUBSTANCIA ACTIVA FARMACEUTICA.
ES8601533A 1985-09-02 1986-09-01 Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" Expired ES2000615A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853531301 DE3531301A1 (de) 1985-09-02 1985-09-02 Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung

Publications (1)

Publication Number Publication Date
ES2000615A6 true ES2000615A6 (es) 1988-03-01

Family

ID=6279944

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8601533A Expired ES2000615A6 (es) 1985-09-02 1986-09-01 Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"

Country Status (10)

Country Link
EP (1) EP0213581A3 (es)
JP (1) JP2526217B2 (es)
AU (1) AU611381B2 (es)
DE (1) DE3531301A1 (es)
DK (1) DK415586A (es)
ES (1) ES2000615A6 (es)
GR (1) GR862238B (es)
MX (1) MX3601A (es)
PT (1) PT83285B (es)
ZA (1) ZA866614B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
DE3584280D1 (de) * 1984-10-26 1991-11-07 Wakunaga Seiyaku Kk Monoklonaler antikoerper gegen menschlichen krebs.
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
JPH0266456A (ja) * 1988-08-31 1990-03-06 Saikin Kagaku Kenkyusho:Kk 疾病動物の一次診断方法、それに使用する診断試薬及びその製造方法
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329184A1 (de) * 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene
DE3416774A1 (de) * 1984-05-07 1985-11-14 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof
DK276185D0 (da) * 1984-11-09 1985-06-19 Novo Industri As Monoklonale antistoffer,fremgangsmaade til fremstilling af disse samt deres diagnostiske anvendelse
JPS61258173A (ja) * 1985-05-10 1986-11-15 Akira Taniuchi モノクロ−ナル抗体およびその製法ならびに用途
US5185432A (en) * 1986-02-26 1993-02-09 Oncogen Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas

Also Published As

Publication number Publication date
DK415586A (da) 1987-03-03
DK415586D0 (da) 1986-09-01
ZA866614B (en) 1987-04-29
JP2526217B2 (ja) 1996-08-21
AU6214086A (en) 1987-03-05
PT83285B (pt) 1989-05-12
GR862238B (en) 1986-12-31
EP0213581A2 (de) 1987-03-11
EP0213581A3 (de) 1988-05-25
PT83285A (pt) 1986-10-01
MX3601A (es) 1993-05-01
JPS6269997A (ja) 1987-03-31
AU611381B2 (en) 1991-06-13
DE3531301A1 (de) 1987-03-05

Similar Documents

Publication Publication Date Title
ES2100174T3 (es) Nuevos anticuerpos reactivos con carcinomas humanos.
ES2054648T3 (es) Procedimiento para la determinacion de una sustancia capaz de fijarse.
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
ES2076142T3 (es) Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.
ES8504461A1 (es) Un procedimiento para obtener un polidoma.
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
NO904368D0 (no) Kryssbundne antistoffer og fremgangsmaate for deres fremstilling.
DE69315213D1 (de) Photoaktivierung von proteinen zu konjugationszwecken
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
HIROMATSU et al. A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
DE3485289D1 (de) Monoklonalantikoerperabfassung fuer diagnostischen gebrauch.
TR200001265T2 (tr) Vasp' a karşı antikorlar, bunların hazırlanması için hibridoma hücreleri.
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
ES2169080T3 (es) Inhibidor de la agregacion de plaquetas estimulada por colageno.
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE96675T1 (de) Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen.
DK440988A (da) Monoklonalt antistof, som er specifikt over for neutrophilocyter
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2006-09-01

FD1A Patent lapsed

Effective date: 19980401

FD1A Patent lapsed

Effective date: 20000601